Sanofi India in its latest Annual General Meeting (AGM) has declared a final dividend of Rs 490 per equity share including special dividend. As per its filing on BSE, “Sanofi India Limited has informed BSE that the Register of Members and Share Transfer Books of the Company shall remain closed from April 16, 2022 to April 26, 2022 (both days inclusive) for the purpose of payment of Rs. Final Dividend (including Special Dividend) and Annual General Meeting (AGM) of the Company to be held on 26th April, 2022.
Sanofi India Dividend
Sanofi India’s dividend of Rs 490 includes a final dividend of Rs 181 and a special dividend of Rs 309 per equity share. Share dividend is a distribution of the earnings of a listed company to a certain class of its shareholders.
Dividend payment is decided by the board of directors of the company as a reward to the shareholders for investing money in its venture. This can be paid in the form of cash or additional stock, as decided by the AGM of the company. Therefore, dividend paying stocks provide an additional opportunity for revenue generation for stock investors. Common shareholders of dividend-paying companies are usually eligible as long as they own the stock prior to the ex-dividend date.
Should you include Sanofi India in your portfolio?
ICICI Securities has placed an ‘Add’ call for Sanofi India with a target price of Rs 8107. Sanofi India Ltd. , The current market price of Rs.7170 is Rs. The time frame given by analysts is one year when Sanofi India Ltd. price can reach its target.
Sanofi India Limited, incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 16790.24 Crore) operating in Pharmaceuticals sector. It is a diversified global healthcare leader focused on developing products that meet people’s health needs. They have a wide range of prescription drugs and vaccines as well as consumer health products.
Sanofi India: Financial
For the quarter ended 31-12-2021, the company reported standalone total income of Rs 704.20 crore, which is -8.45 per cent lower than last quarter total income of Rs 769.20 crore and 4.39 per cent lower than the corresponding quarter last year. 736.50 crore Rs. The Company has reported a Net Profit After Tax of Rs 90.40 Crore in the latest quarter.
Sanofi India: Investment Logic
The brokerage maintains an ‘Add’ rating with a target price of Rs 8,107/share based on 30x Jun’23E EPS. The major downside risks are inclusion of key drugs in NLEM, product concentration, government interference and presence of unlisted promoter company.
Disclaimer:Disclaimer: The views and investment tips of experts in this News18.com report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decision.
read all breaking news, today’s fresh news And Assembly Election Live Updates Here.